When Small Meets Speedy

Source: MGH Center for Systems Biology, by Yvonna Fisher-Jeffes. AI-generated summary by biochip.com, published May 12, 2026. Not independently reviewed.

Massachusetts General Hospital scientists tested a portable diagnostic magnetic resonance device that identified cancer-associated cellular markers from tiny patient samples in less than an hour. The coffee-mug-sized system, called DMR, was evaluated in 70 patients with suspected abdominal malignancy at MGH. Instead of relying on a larger tissue biopsy alone, it analyzed cells collected through fine needle aspiration, a minimally invasive procedure that removes cells with a thin needle. The device combines antibodies, proteins that recognize selected biological targets, with magnetic particles that make those targets easier to detect. A four-marker panel identified cancerous cells with 96 percent accuracy and was validated in a separate patient group. The team reported that this turnaround was much faster than routine pathology, which can take several days. By pairing magnetic sensing with small-volume samples and a simple digital interface, the project aimed to address a persistent clinical problem: getting a reliable answer without requiring more tissue or making patients wait.

A diagnostic problem measured in days

For someone awaiting the outcome of a biopsy, the delay is not merely inconvenient. Standard pathology, the laboratory examination of patient specimens, may take days because samples are collected, prepared, and processed in batches. In the MGH study, biopsy specimens went to the laboratory for conventional testing while fine needle aspiration samples were run through the DMR system.

Obtaining enough usable material is another obstacle. Tumors can contain a mixture of cancer cells, inflammatory cells, and other noncancerous cells, so two samples from similar-looking lesions may contain very different numbers of tumor cells. Cesar Castro, an MGH physician and joint first author, said this variability has traditionally created a need for larger amounts of tissue, especially when testing proteins.

What the DMR device does

DMR stands for diagnostic magnetic resonance. Its underlying principle resembles magnetic resonance imaging, or MRI, in that it uses magnetic behavior to generate measurable signals, but it is designed as a compact test for cellular markers rather than a body scanner. Think of it as attaching tiny magnetic flags to the biological clues clinicians want to find.

The system has antibodies that target particular cancer markers and small magnetic particles that generate a signal. When the components mix with a patient sample, the particles bind to the antibodies through the team's labeling chemistry. If an antibody finds its intended marker on or in a cell, the attached particles mark that interaction, and the DMR measures and quantifies the resulting magnetic signal.

Making weak biological signals visible

Detecting a marker is difficult when it is scarce, which is exactly the situation that can arise in a small needle aspirate. Hakho Lee, an assistant professor at MGH who led the system's development, said the labeling chemistry allowed the team to load more magnetic particles onto antibodies. More particles create a stronger signal, allowing the device to register low levels of marker-particle interaction.

This signal amplification matters because a useful diagnostic cannot depend on a perfectly clean or abundant sample. Fine needle aspiration is less invasive than removing a larger piece of tissue, but its smaller yield puts greater pressure on the measurement technology. The DMR approach was built to extract quantitative information from those limited cellular samples.

Why one marker was not enough

The early DMR prototype could detect only one or two cancer markers. The MGH researchers found that this was insufficient because cancer biology varies between patients and even among samples classified under the same broad diagnosis. Rather than seeking one universal marker, they looked for a pattern across several markers.

After testing a panel of 12 cancer markers, the team identified a combination of four that detected cancerous cells with 96 percent accuracy. The result was subsequently validated in a separate group of patients. That panel-based strategy treats diagnosis less like finding a single identifying fingerprint and more like recognizing a combination of features that together distinguishes a suspect from a crowd.

Faster results, fresher specimens

The reported under-one-hour workflow contrasts with the three- to four-day timeframe Castro described for standard cytology, the examination of cells for signs of disease. He noted that conventional specimens may wait until enough samples accumulate for batch processing. That waiting period has consequences beyond patient anxiety.

Castro said protein markers showed marked degradation when specimens were left over time. Laboratories can stabilize samples through a process called fixing, but rapid analysis offers another route: measure the markers before they degrade. In that sense, speed is not simply a convenience feature, it can help preserve the biological information the test is meant to read.

Why This Matters

The central advance is a sensing platform designed around a real clinical constraint: physicians often have only a small, messy sample and need a usable result quickly. The DMR system brought together targeted antibodies, magnetic nanoparticles, and compact magnetic readout in a format small enough to sit on a bench. It also could interface with a smartphone or tablet, allowing results to be obtained at the testing site and transferred directly to a doctor.

The study does not mean every cancer can be diagnosed with a single compact device or with the same four markers. Its clinical test focused on patients with suspected abdominal malignancy, and the useful marker combination emerged from that work. Still, the result illustrates how carefully chosen marker panels and sensitive magnetic detection could reduce the tradeoff between minimally invasive sampling and diagnostic performance.

What comes next

The future value of DMR will depend on how well marker panels perform across additional cancer settings and how the device fits into routine clinical workflows. Its promise lies in making molecular information available while the specimen is still fresh and the patient is still nearby. For diagnostic technologies, smaller hardware matters most when it helps deliver a faster, clearer answer at the point where clinical decisions are being made.

Topics: Cancer · Diagnostics & precision medicine

Start here: What is a biochip?